Cost of screening and treatment of cervical dyskaryosis in Germany

Human papillomavirus (HPV) infection is the principal cause of cervical cancer. Clinical trials with HPV vaccines have shown high efficacy against HPV-induced precancerous cervical lesions. Before implementing a vaccination programme, up-to-date data on cervical dyskaryosis, incidence and annual treatment costs are needed. We assessed resource use and costs for 12 months following diagnosis for women with abnormal Pap smears in Germany based on a sample of 138 women who had received abnormal results on Pap smears taken during March and April of 2004. Most women had a Pap HID (57%) vs Pap 111 (20%) or Pap IV (23%). Women with a Pap IV consulted their gynaecologist more frequently than those with a Pap III or Pap IIID (5.6 visits vs 4.2 and 4.6 visits, respectively). Only 9% of patients underwent colposcopy plus biopsy; this may be due to the lack of histological assessment by coloposcopy and biopsy done currently in Germany. More women in the Pap IV group had a cold knife conisation, compared with those in the Pap HID group, (84% vs 27%) hysterectomy (22% vs 4%) and laser coagulation (12.5% vs 4%). Median treatment duration was shorter for women with a Pap III than for those with Pap IIID and IV (3 vs 5 months, respectively). Overall, 28.3% of the women were hospitalised (median 5; range 1-33 days). The estimated average annual cost per patient was is an element of 1,055, is an element of 943 and is an element of 3,174 for Pap III, IIID and IV, respectively. The cost of managing precancerous cervical lesions in Germany was shown to be high.

Human papillomavirus; Cervical cancer; Cervical cancer screening; Cervical dyskaryosis; Retrospective study; Resource use; Treatment cost

[1] Schiller J.T., Davies P.: “Delivering on the promise: HPV vaccines and cervical cancer”. Nat. Rev. Microbiol., 2004, 2, 343.

[2] Walboomers J.M., Jacobs M.V., Manos M.M. et al.: “Human papillomavirus is a necessary cause of invasive cervical cancer worldwide”. J. Pathol., 1999, 189, 12.

[3] Kuper H., Adami H.O., Trichopoulos D.: “Infections as a major preventable cause of human cancer”. J. Intern. Med., 2000, 248, 171.

[4] Jacobs M.V., Roda Husman A.M., van den Brule A.J., Snijders P.J., Meijer C.J., Walboomers J.M.: “Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes”. J. Clin. Microbiol., 1995, 33, 901.

[5] Munoz N., Bosch F.X., de Sanjose S. et al.: “Epidemiologic classification of human papillomavirus types associated with cervical cancer”. N. Engl. J. Med., 2003, 348, 518.

[6] Von Krogh G.: “Management of anogenital warts (condylomata acuminata)”. Eur. J. Dermatol., 2001, 11, 598.

[7] Clifford G.M., Gallus S., Herrero R. et al.: “Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis”. Lancet, 2005, 366, 991.

[8] ACNielsen ACNielsen Gebiete Deutschland. http://www.acnielsen. de/company/acnielsengebiete.shtml.

[9] Kassenärztliche Bundesvereinigung Einheitlicher Bewertungsmaßstab für ärztliche Leistungen. http://www.kbv.de/ebm2000plus/EBMGesamt.htm.

[10] De Haen C. Gebührenordnung für Ärzte. http://e-bis.de/goae/defaultFrame.htm.

[11] German Drug Related Groups. Available at: http://www.g-drg.de/.

[12] Destatis Bruttoinlandsprodukt, Bruttonationaleinkommen, Volkseinkommen ab 1950.http://www.destatis.de/download/d/vgr/biplangereihe.xls.

[13] Barber J.A., Thompson S.G.: “Analysis of cost data in randomized trials: an application of the non-parametric bootstrap”. Stat. Med., 2000, 19, 3219.

[14] Infektiologische Empfehlungen und Leitlinie zur Diagnostik und Therapie in Gynacologie und Geburtshilfe, 5. aktualisierte Fassung, 2006, 17.

[15] Bergeron C., Wiener H., Schenck U., Klinkhamer P., Bulten J., Arbyn M., European Guidelines for Quality Assurance in Cervical Cancer Screening 2003. Available at www.Cancer-network.de/cervical/chapt8.

[16] Schenck U., Von Karsa L.: “Cervical cancer screening in Germany”. Eur. J. Cancer, 2000, 36, 2221.

[17] EUROSTAT: Statistical Office of the European Communities, Luxembourg, 2006. Available at: http://epp.eurostat.cec.eu.int/extraction/evalight/EVAlight.jsp?A=1&language=en&root=/theme3/proj/proj_top_pop.

[18] Petry K.U., Böhmer G., Iftner T., Davie P., Brummer O., Kühnle H.: “Factors associated with an increased risk of prevalent and incident grade III cervical intraepithelial neoplasia and invasive cancer among women with Papanicolaou tests classified as grades I or II cervical intraepithelial neoplasia”. Am. J. Obstet. Gynecol 2002, 186, 28.

[19] Petry K.U., Menton S., Menton M. et al.: “Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients”. Br. J. Cancer, 2003, 88, 1570.

[20] Ikenberg H.: “Status of papillomaviruses and their diagnosis in preventive screening” (in German). Ther. Umsch., 2002, 59, 489.

[21] HS Cervical Cancer Screening Programme 2006. Available at: http://www.cancerscreening.nhs.uk/cervical/#cost.

[22] Bergeron C., Wiener H., Schenck U., Klinkhamer P., Bulten J., Arbyn M., European Guidelines for Quality Assurance in Cervical Cancer Screening 2003. Available at www.Cancer-network.de/cervical/chapt1.

[23] Brown R.E., Breugelmans J.G., Theodoratou D., Benard S.: “Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK”. Curr. Med. Res. Opin., 2006, 22, 663.

[24] Rousseau A., Bohet P., Merlière J. et al.: “Evaluation du dépistage organisé et du dépistage individuel du cancer du col de l’utérus : utilité des données de l’Assurance maladie”. Bull. Epidemiol. Hebdomadaire, 2002, 19, 81.

[25] Bergeron C., Breugelmans J.G., Bouee S., Lorans C., Benard S., Remy V.: “Cervical cancer screening and associated treatment costs in France”. Gynecol. Obstet. Fertil., 2006, 34, 1036.

[26] Villa L.L., Costa R.L.R., Petta C.A. et al.: “High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up”. Br. J. Cancer, 2006, 95,1459.

[27] The Future II Study Group: “Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions”. N. Engl. J. Med., 2007, 356, 1915.